- Home
- EXAS vs LEGN Comparison
EXAS vs LEGN Comparison
Compare EXAS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXAS | LEGN |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EXAS | LEGN |
|---|---|---|
| Price | $101.72 | $22.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 13 |
| Target Price | ★ $77.94 | $69.58 |
| AVG Volume (30 Days) | ★ 7.2M | 2.6M |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,082,033,000.00 | $909,045,000.00 |
| Revenue This Year | $19.40 | $68.83 |
| Revenue Next Year | $13.51 | $51.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.47 | ★ 74.75 |
| 52 Week Low | $38.81 | $21.19 |
| 52 Week High | $102.66 | $45.30 |
Technical Indicators
Market Signals| Indicator | EXAS | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 87.35 | 31.12 |
| Support Level | $101.28 | $21.19 |
| Resistance Level | $101.93 | $28.97 |
| Average True Range (ATR) | 0.36 | 1.23 |
| MACD | -1.36 | -0.12 |
| Stochastic Oscillator | 78.00 | 17.35 |
Price Performance
Historical ComparisonAbout EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.